In short
ELI Lilly And Company (LLY) has revenue up 44.7% to $65.2B and net income up 94.9% to $20.6B year on year. Its net margin is 31.7%, and it trades at 46.0× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this
Compare: JNJ vs LLY · LLY vs PFE · ABBV vs LLY · LLY vs MRK
Valuation
HealthcareLive · Yahoo FinancePrice
$1,347.11
$1.20T
26.8x
0.51%
52-Week Range
Decision Context
Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — LLY
Inflationary BoomStrengths
EPS (Diluted): $22.95 (+96.0% YoY) — Earnings per share rose 96% — each share earned more.
Net Income: $20.6B (+94.9% YoY) — Profit grew 95% — the company kept more of each dollar earned.
Operating Cash Flow: $16.8B (+90.7% YoY) — Operating cash flow grew 91% — the business generated more cash from day-to-day operations.
Revenue: $65.2B (+44.7% YoY) — Revenue grew 45% — the company sold more goods or services than the prior year.
Total Assets: $112.5B (+42.9% YoY) — Total assets grew 43% — the company's resource base expanded.
Weaknesses
Stock is near its 52-week high (1449.68) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Opportunities
No clear opportunities identified at this time.
Threats
No significant threats flagged.
Year-over-Year Changes
EPS (Diluted)
$22.95
was $11.71
Earnings per share rose 96% — each share earned more.
Net Income
$20.6B
was $10.6B
Profit grew 95% — the company kept more of each dollar earned.
Operating Cash Flow
$16.8B
was $8.8B
Operating cash flow grew 91% — the business generated more cash from day-to-day operations.
Revenue
$65.2B
was $45.0B
Revenue grew 45% — the company sold more goods or services than the prior year.
Total Assets
$112.5B
was $78.7B
Total assets grew 43% — the company's resource base expanded.
Risk Flags
0 high · 0 medium · 1 low- ○ Low
Stock is near its 52-week high (1449.68) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Technical Signals
Daily closes · 1-year dataELI Lilly And Company: common questions
Is ELI Lilly And Company profitable?
Yes. ELI Lilly And Company made a net profit of $20.6B in its latest fiscal year (fiscal 2025), a net margin of 31.7%.
Is ELI Lilly And Company's revenue growing?
Yes. Revenue grew 44.7% year on year, to $65.2B.
What is ELI Lilly And Company's P/E ratio?
ELI Lilly And Company trades at 43.7× its trailing twelve-month earnings. In other words, the share price is about 44 times the profit per share the company earned over the past year.
Does ELI Lilly And Company pay a dividend?
Yes. ELI Lilly And Company's forward dividend yield is 0.51%, the expected annual dividend as a share of the current share price.
Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — LLY
2026-09-30
filed 2026-10-29
Revenue
$65.2B
Net Income
$20.6B
EPS
$22.95
2026-06-30
filed 2026-08-05
Revenue
$65.2B
Net Income
$20.6B
EPS
$22.95
2026-03-31
filed 2026-04-30
Revenue
$65.2B
Net Income
$20.6B
EPS
$22.95
2025-12-31
filed 2026-02-12
Revenue
$65.2B
Net Income
$20.6B
EPS
$22.95
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade LLY
Links open broker research pages. Not an endorsement or recommendation.
Research ELI Lilly And Company
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.